CureVac (CVAC) has released an update.
CureVac N.V., a biopharmaceutical company specializing in mRNA technology, has announced the latest trial dates for its patent litigation against Pfizer/BioNTech. The U.S. trial is scheduled for March 3, 2025, after a settlement with Acuitas Therapeutics, while the European Patent Office will review patent validity on March 25, 2025. Additionally, a UK trial began on July 10, 2024, with a judgment expected later in the same year.
For further insights into CVAC stock, check out TipRanks’ Stock Analysis page.
